# Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma

> **NCT07644897** · PHASE2 · RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 55 (estimated)

## Conditions studied

- Melanoma
- Immune-related Adverse Event
- Immune Checkpoint Inhibitor

## Interventions

- **DRUG:** Thymosin Alpha 1 and Anti-PD-1 monoclonal antibody

## Key facts

- **NCT ID:** NCT07644897
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-05-30
- **Primary completion:** 2027-05-30
- **Final completion:** 2027-09-30
- **Target enrollment:** 55 (ESTIMATED)
- **Last updated:** 2026-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07644897

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07644897, "Thymosin Alpha 1 Combined With Anti-PD-1 Monoclonal Antibody in Elderly Patients With Advanced Melanoma". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07644897. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*